The second interim analysis of Italian participants enrolled in the real-world, Pan-European, prospective, observational, Phase 4 PEARL study of fremanezumab effectiveness
Fremanezumab was effective and well tolerated in Italian clinical practice, with results in line with those previously reported for fremanezumab in a real-world setting.
Authors
- Gianluca Coppola (ORCID: https://orcid.org/0000-0002-8510-6925)
- Sabina Cevoli (ORCID: https://orcid.org/0000-0003-4668-4295)
- Anna Ambrosini (ORCID: https://orcid.org/0000-0003-4231-2187)
- Mario Cepparulo
- Roberto De Simone (ORCID: https://orcid.org/0000-0002-0954-8668)
- Cristina Tassorelli (ORCID: https://orcid.org/0000-0003-1513-2113)
- Pinar Kokturk
- Simona Guérzoni (ORCID: https://orcid.org/0000-0001-9589-2782)
- Innocenzo Rainero (ORCID: https://orcid.org/0000-0001-6074-9628)
- Marco Bartolini (ORCID: https://orcid.org/0000-0003-2518-6369)
- Fabrizio Vernieri (ORCID: https://orcid.org/0000-0002-9594-9336)
- Maria Pia Prudenzano (ORCID: https://orcid.org/0000-0001-9259-8158)
- Renata Rao
- Florindo d’Onofrio (ORCID: https://orcid.org/0009-0007-1647-3389)
- Antonio Granato
Institutions
- Marche Polytechnic University (IT)
- University of Trieste (IT)
- Università Campus Bio-Medico (IT)
- University of Pavia (IT)
- Istituto Neurologico Mediterraneo (IT)
- Ospedale di Cattinara (IT)
- 5T Torino (Italy) (IT)
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
- Azienda Ospedaliero-Universitaria di Modena (IT)
- Teva Pharmaceuticals (Netherlands) (NL)
- Azienda Ospedaliera S.Giuseppe Moscati (IT)
- Federico II University Hospital (IT)
- Istituto delle Scienze Neurologiche di Bologna (IT)
- Torino e-district (IT)
- Campus Bio Medico University Hospital (IT)
- University of Turin (IT)
- University of Bari Aldo Moro (IT)
- University of Naples Federico II (IT)
Publication Details
- Journal
- Neurological Sciences
- Published
- 2025-10-17
- DOI
- https://doi.org/10.1007/s10072-025-08504-0
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Teva Pharmaceutical Industries